The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 29th year as an NCI-designated CCC and is now requesting continued federal support for the next five years. The OSUCCC named its 4th Director, Michael A. Caligiuri, M.D. in July, 2003 while retaining the former Center Director, Clara D. Bloomfield, M.D., as a Senior Advisor to the OSUCCC. The overall goal remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 183 OSUCCC members are currently served by 13 shared resources and are distributed among 6 Research Programs: Cancer Control, Experimental Therapeutics, Immunology, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention and Viral Oncogenesis. Since the last competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of more than 90 new cancer research faculty to OSU; 2) more than a 230% increase in patient accrual to investigator-initiated trials; 3) the addition of 6 new shared resources at an institutional investment of over $10.8 M; 4) a 144% increase in total NCI funding and a 65% increase in peer-reviewed funding. The OSUCCC has also seen tremendous growth in institutional commitment since 1999 as demonstrated by: 1) a new formal role for the OSUCCC Director within OSU, providing complete oversight of the University-wide cancer funding initiatives, opportunities and cancer grant submissions; 2) A seat on the eight-member Medical Center Executive Committee which meets every week with the Senior VP of Health Sciences to plan and evaluate the entire Health System's direction (cancer is the only discipline represented on this Committee); 3) a written commitment for the expansion of the Cancer Program facilities that will result in more than a four-fold increase over the current square footage under control of the OSUCCC Director at a cost of approximately $350 M; 4) interim laboratory and office space for recruitment until the new facility is constructed; 5) an additional $7.0 M of cash annually from OSU for research and infrastructure expansion; and 6) twenty senior faculty slots under the control of the OSUCCC Director, each provided with $100,000 of guaranteed salary in perpetuity. With these new resource commitments in place, the OSUCCC is poised for significant growth and expansion in the next 5 years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-30S2
Application #
7126643
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2009-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
30
Fiscal Year
2005
Total Cost
$249,839
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Das Ghatak, Piya; Mathew-Steiner, Shomita S; Pandey, Priyanka et al. (2018) A surfactant polymer dressing potentiates antimicrobial efficacy in biofilm disruption. Sci Rep 8:873
Bhattacharya, Mohini; Berends, Evelien T M; Chan, Rita et al. (2018) Staphylococcus aureus biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. Proc Natl Acad Sci U S A 115:7416-7421
Kodigepalli, Karthik M; Li, Minghua; Bonifati, Serena et al. (2018) SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle 17:2564-2576
Woodard, John L; Huntsman, Andrew C; Patel, Pratiq A et al. (2018) Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones. Bioorg Med Chem 26:2354-2364
Miller, Katherine E; Kelly, Benjamin; Fitch, James et al. (2018) Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. Cold Spring Harb Mol Case Stud 4:
Chen, Xiang; Wei, Jia; Li, Chenglong et al. (2018) Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. Int J Oncol 52:571-578
Poorman, Caroline E; Ethun, Cecilia G; Postlewait, Lauren M et al. (2018) A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Ann Surg Oncol 25:520-527
Stover, Daniel G; Gil Del Alcazar, Carlos R; Brock, Jane et al. (2018) Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 4:10
van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380
Rohan, Thomas E; Miller, Christopher A; Li, Tiandao et al. (2018) Somatic mutations in benign breast disease tissue and risk of subsequent invasive breast cancer. Br J Cancer 118:1662-1664

Showing the most recent 10 out of 2602 publications